Cardio3 BioSciences and Mayo Foundation For Medical Education And Research | Date: 2010-05-20
This document is related to a method for determining the cardio-generative potential of mammalian cells which comprises the assessment of a CARdiac generation Potential Index (CARPI) as a function of the quantification of the expression of genes of said cells. It also relates to a method for quantitatively assessing the modification of this cardio-generative potential and the cardiogenic potential of a treatment aiming at cellular differentiation.
Cardio3 BioSciences | Date: 2010-04-29
The invention relates to an injection catheter for delivering a therapeutic agent into a substrate, comprising one or more lumens and a curved delivery element, said lumen serving as a guide for said curved delivery element outside of the substrate; said curved delivery element comprising openings on its distal tip, said distal tip comprising a distal zone and a proximal zone, said injection catheter being characterized in that the specific surface in said distal zone of said distal tip of said curved delivery element is higher than the specific surface in said proximal zone of said distal tip of said curved delivery element. The invention also relates to a process for delivering a therapeutic agent into a substrate.
News Article | January 8, 2015
08.01.2015 - Belgian cell therapy specialist Cardio3 Biosciences joins the immuno-oncology arena with the acquisition of Celdara Medical's cancer division Oncyte for US$180m. With the deal comes Oncyte's portfolio of immuno-oncology product candidates: three autologous Chimeric Antigen Receptor(CAR) T-Cell cell therapy products and an allogeneic T-Cell platform, targeting a broad range of cancer indications. The CAR technology developed by Oncyte uses human natural killer cell receptors which, unlike traditional CAR technologies, have the potential to target a broad range of liquid and solid cancers via a human natural receptor that targets ligands present on most tumour types. Oncyte’s most advanced autologous CAR T-Cell drug candidate, CM-CS1, uses a specific human Natural Killer cell receptor, NKG2D, that targets tumour antigens expressed in most liquid and solid cancers. The drug candidate is set to start phase I trials in the first quarter of 2015, with the final results expected in mid-2016. For Oncyte, Cardio3 will spend up to US$180m (€153m). There will be an upfront payment of US$6m in cash and US$4m in Cardio3 shares. For the successful development of the lead product CM-CS1, Cardio3 will pay up to US$50m in development and regulatory milestones until market approval, as well as US$21m for each of the other products. Celdara is also eligible for up to US$80m in sales milestones when net sales will exceed US$1bn, as well as royalties. "This acquisition positions us in a second therapeutic area characterised by significant unmet medical need, while allowing us to leverage our leading cell therapy capabilities to drive the development of this potentially game-changing immuno-oncology technology," commented Christian Homsy, CEO of Cardio3 BioSciences.
News Article | January 6, 2015
Get the latest on Biotech & Pharma Deals, Clinical Trials, FDA Decisions, and Key Regulatory Issues sent straight to your Inbox. Join over 150,000 biotech professionals who subscribe to FierceBiotech for FREE! Click here to see a sample.
Agency: Cordis | Branch: FP7 | Program: CP-TP | Phase: NMP.2013.2.2-1 | Award Amount: 8.69M | Year: 2013
The Advanced Materials for Cardiac Regeneration (AMCARE) consortium aims to establish a translational research program to develop truly restorative therapies for acute myocardial infarction repair (MI) by optimising cardiac progenitor cell (CPC) therapy using smart biomaterials and advanced drug delivery, and coupling these therapeutics with minimally-invasive surgical devices. Two distinct biomaterial delivery systems for CPCs will be investigated in the AMCARE work programme including HA-based patches (CardioPatch) and HA-hydrogels (CardioGel). We also propose to develop two prototypes of new surgical devices [C-CathGel and SPREDS] that will ensure a minimally invasive delivery and fixation approach that is safe and effective for each therapeutic. The combinations of advanced material carriers and surgical devices will be assessed in a large animal model of acute-MI to best align our approach to clinical translation. The novel formulations and delivery methods will help post-MI patients in restoring cardiac function by targeting for repair the underlying myocardium damage, and could potentially decrease morbidity and mortality in the future. These goals will be achieved by integrating numerous areas of materials science and stem cell biology as well as leaders in the field of medical devices, biomaterials and cardiovascular regeneration. We thus aim to improve long-term healthcare of EU citizens by offering a revolutionary therapeutic modality for the treatment of acute-MI.